South Dakota Department of Social Services, Division of Medicaid Services
Pharmacy & Therapeutics (P&T) Committee Meeting Minutes

Friday, September 8, 2023
1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD	X	Matthew Stanley, DO	X
Dana Darger, RPh, Chair	X	Deidre Van Gilder, PharmD	X
Bill Ladwig, RPh	X	Clarissa Barnes, MD, DSS Staff	X
Kelley Oehlke, PharmD	X	Mary Carpenter, MD, DSS Staff	X
Lenny Petrik, PharmD	X	Mike Jockheck, DSS Staff	X
Heather Preuss, MD	X	Taylor Koerner, DSS Staff	X

Administrative Business

Darger called the meeting to order at 1:02 pm. The minutes of the March meeting were presented. Ladwig made a motion to approve. Baack seconded the motion. The motion was unanimously approved.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report from April 1, 2023, to June 30, 2023. A total of 1,848 PAs were reviewed of which 89 requests (4.8%) were received via telephone, 102 requests (5.5%) were received via fax, 649 (35.2%) were reviewed electronically, and 1,007 (54.5%) PAs were received via ePA. There was a 25% decrease in PAs received compared to the previous quarter which was the result of the PAs leveling off after the 25% increase from the ePA implementation.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from April 1, 2023, to June 30, 2023. The top five therapeutic classes based on paid amount were disease-modifying anti-rheumatic agents, skin and mucous membrane agents, atypical antipsychotics, cystic fibrosis correctors, and amphetamines. These top 15 therapeutic classes comprise 22.5 % of total claims. The committee also reviewed the top 50 drugs based on amount paid and number of claims. The top 50 drugs by amount paid make up 9.7% of total claims. There was an increase in hepatitis C medication utilization. Baack commented on the automatic screening performed for hepatitis C for all pregnant mothers.

Old Business

Opioid CDUR edits

The committee reviewed changing the opioids and benzodiazepines CDUR edit from message to soft edit. Baack made a motion to accept the change from message to soft edit for opioids and benzodiazepines. Ladwig seconded the motion. Darger inquired if there was any public testimony. There was none. The motion was approved unanimously.

Opioid update

The committee reviewed 2Q2023 opioid outcomes compared to previous quarters from the opioid initiatives. There was a decrease in opioid utilization and utilizers during 2Q2023 with corresponding decrease in total eligibility and utilizers. Darger inquired if there was any public comment. There was none.

New Business

Vyvanse dose limit

The committee reviewed members exceeding Vyvanse 70mg/day. Darger commented literature did not support any advantages in taking doses over 70mg/day. Stanley was skeptical that increase in doses are clinically necessary. After discussion, Lagwig made a motion to add a dose limit of 70mg/day on Vyvanse. Stanley seconded the motion. Darger inquired if there were any public comments. There were none. The motion was approved unanimously.

Qelbree

Jockheck clarified the next agenda items. The committee reviewed the utilization of Qelbree and proposed step therapy with trial of atomoxetine or stimulants. Stanley commented regarding the onset of action, stimulants are immediate acting while the full response from atomoxetine takes 6 – 12 weeks; and to ensure accounting for side effects. Darger and Stanely discussed allowing different trial durations for atomoxetine vs stimulants; 30-day trial for stimulant and 60- day trial for atomoxetine. Darger inquired if there were any public comments. Patrick Harvey with Medical Affairs from Supernus Pharmaceuticals provided public testimony. Stanley made a motion to add step therapy to Qelbree with 60-day trial of atomoxetine or 30-day trial of stimulants in the last 180 days. Baack seconded the motion. The motion was approved unanimously.

Adalimumab

Jockheck provided information that there is a significant difference between the net price of biosimilars to brand. The proposed step therapy is a trial and failure of Humira before biosimilars. Darger inquired if there were any public comments. Baack made a motion add this step therapy and Van Gilder seconded the motion. The motion was approved unanimously.

Growth hormones

The committee reviewed utilization of growth hormones and proposed step therapy of the preferred products. Baack commented on the current shortages of both Genotropin and Norditropin and to allow for substitution of the preferred product when shortages occur. Baack made the motion to add Genotropin and Norditropin as preferred. Petrik seconded the motion. Darger inquired if there were any public comments. Paul Miner, National Director for Ascendis Pharmacy, provided public testimony. After discussion, Baack made the motion for trial and failure of one preferred product before allowing a second line product. Preuss seconded the motion. The motion was approved unanimously.

Rukobia

Rukobia clinical information was presented for review. Due to the narrow use profile of Rukobia, the need for clinical PA was discussed. Baack made the motion to add PA like health plan A. Van Gilder seconded the motion. Darger inquired if there was any public comment. There was none. The motion was approved unanimously.

Sotyktu

Sotyktu clinical information was presented for review. The committee discussed adding PA using the state's general psoriasis PA criteria for Sotyktu. The committee also reviewed the general psoriasis PA criteria to determine if any changes should be made. After review, Baack made the motion to carry on with the current plaque psoriasis PA and to add this PA criteria for Sotyktu. Van Gilder seconded the motion. Darger inquired if there was any public comment. There was none. The motion was approved unanimously.

Darger's last meeting will be in December. Van Gilder will assume Chairperson duties going forward.

Adjournment

The next meeting is scheduled on December 8, 2023, in Sioux Falls. The March meeting is tentatively scheduled for March 1, 2024. Baack made the motion to adjourn the meeting and Van Gilder seconded the motion. The motion to adjourn the meeting was unanimous, and the meeting adjourned at 2:32 pm CT.